Cagrilintide Protocol
Amylin-receptor agonist studied for appetite regulation, often alongside GLP-1 agonists in combination research.
- Standard dose
- 2.5 mg
- Frequency
- 1× weekly, subcutaneous
- Route
- subcutaneous
- Cycle
- 12–24 weeks
- Vial
- 5 mg
Evidence Level: Emerging Evidence
Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.
Human evidence: Phase 2/3 trial data, mostly as the amylin component of the CagriSema combination.
Animal evidence: Preclinical amylin-pathway studies preceding human trials.
Introduction & Mechanism of Action
Amylin-receptor agonist studied for appetite regulation, often alongside GLP-1 agonists in combination research.
Long-acting amylin analog that slows gastric emptying and promotes satiety via a mechanism distinct from and complementary to GLP-1 agonism.
Receptors/targets: Amylin receptor (calcitonin receptor / RAMP complex)
Areas of Research Interest
- Amylin-pathway research
- Appetite-regulation studies
- Combination weight-management trials
Benefits Reported in Research
- Appetite-regulation research
- Amylin-pathway studies
- Combination metabolic research
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 0.5–4.5 mg
Reported frequency: 1× weekly, subcutaneous
Reported cycle duration: 12–24 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on Cagrilintide reports administration at 0.5–4.5 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | subcutaneous | 1× weekly, subcutaneous | 2.5 mg |
Reconstitution Reference
Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for Cagrilintide →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 5 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 2.50 mg/mL.
- 03
Reported Research Administration
Published research describes 1× weekly, subcutaneous administration via subcutaneous route, at 2.5 mg per administration.
- 04
Cycle Reference
Published protocols describe a cycle duration of 12–24 weeks. Consult a physician before beginning any new research cycle.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Nausea
- Vomiting
- Injection-site reaction
- Decreased appetite
Contraindications
- Pregnancy
- Known hypersensitivity to amylin analogs
Drug interactions
- GLP-1 receptor agonists (e.g. semaglutide) — combined use is the primary research context (CagriSema) and may compound gastrointestinal side effects
Safety
- Gastrointestinal intolerance
- Injection-site reactions
- Theoretical hypoglycemia risk when combined with GLP-1 agonists
Most human data is from combination programs (e.g. with semaglutide); standalone long-term safety data is more limited.
Expected Results & Comparison
Cagrilintide is rarely studied standalone for weight management — most trial data comes from the CagriSema combination, so its independent effect size is less established than GLP-1/GIP agonists studied alone.